Media coverage about C.R. Bard (NYSE:BCR) has been trending somewhat positive on Sunday, Accern reports. The research firm identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. C.R. Bard earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave media stories about the medical instruments supplier an impact score of 46.9622199696124 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the news articles that may have effected Accern’s rankings:

Shares of C.R. Bard (NYSE BCR) traded up 0.62% on Friday, hitting $323.91. 532,025 shares of the stock traded hands. The firm’s 50 day moving average is $320.21 and its 200 day moving average is $294.66. C.R. Bard has a 52 week low of $203.63 and a 52 week high of $324.13. The firm has a market capitalization of $23.54 billion, a PE ratio of 42.52 and a beta of 0.60.

C.R. Bard (NYSE:BCR) last announced its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $2.92 EPS for the quarter, topping the Zacks’ consensus estimate of $2.84 by $0.08. The business had revenue of $979.70 million for the quarter, compared to analyst estimates of $976.53 million. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.54 earnings per share. On average, analysts expect that C.R. Bard will post $11.84 EPS for the current fiscal year.

A number of research firms have issued reports on BCR. Zacks Investment Research upgraded shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 target price for the company in a research report on Tuesday, June 13th. Jefferies Group LLC reiterated a “hold” rating on shares of C.R. Bard in a research report on Thursday, August 3rd. BidaskClub upgraded shares of C.R. Bard from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 8th. Finally, BMO Capital Markets reiterated a “hold” rating and issued a $317.00 target price on shares of C.R. Bard in a research report on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. C.R. Bard currently has a consensus rating of “Hold” and a consensus target price of $285.67.

TRADEMARK VIOLATION NOTICE: This piece was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at

In related news, insider John P. Groetelaars sold 23,687 shares of the business’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the transaction, the insider now directly owns 31,445 shares in the company, valued at $10,022,464.85. The sale was disclosed in a filing with the SEC, which is available through this link. 0.80% of the stock is currently owned by insiders.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Insider Buying and Selling by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Stock Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related stocks with our FREE daily email newsletter.